Genomic analysis of nontypeable pneumococci causing invasive pneumococcal disease in South Africa, 2003–2013 by unknown
RESEARCH ARTICLE Open Access
Genomic analysis of nontypeable
pneumococci causing invasive
pneumococcal disease in South Africa,
2003–2013
Thabo Mohale1,2*, Nicole Wolter1,2, Mushal Allam1, Kedibone Ndlangisa1,2, Penny Crowther-Gibson3,
Mignon du Plessis1,2 and Anne von Gottberg1,2
Abstract
Background: The capsular polysaccharide is the principal virulence factor of Streptococcus pneumoniae and a
target for current pneumococcal vaccines. However, some pathogenic pneumococci are serologically nontypeable
[nontypeable pneumococci (NTPn)]. Due to their relative rarity, NTPn are poorly characterized, and, as such, limited
data exist which describe these organisms. We aimed to describe disease and genotypically characterize NTPn
causing invasive pneumococcal disease in South Africa.
Results: Isolates were detected through national, laboratory-based surveillance for invasive pneumococcal
disease in South Africa and characterized by whole genome analysis. We predicted ancestral serotypes (serotypes
from which NTPn may have originated) for Group I NTPn using multilocus sequence typing and capsular region
sequence analyses. Antimicrobial resistance patterns and mutations potentially causing nontypeability were
identified. From 2003–2013, 39 (0.1 %, 39/32,824) NTPn were reported. Twenty-two (56 %) had partial capsular
genes (Group I) and 17 (44 %) had complete capsular deletion of which 15 had replacement by other genes
(Group II). Seventy-nine percent (31/39) of our NTPn isolates were derived from encapsulated S. pneumoniae.
Ancestral serotypes 1 (27 %, 6/22) and 8 (14 %, 3/22) were most prevalent, and 59 % (13/22) of ancestral serotypes
were serotypes included in the 13-valent pneumococcal conjugate vaccine. We identified a variety of mutations
within the capsular region of Group I NTPn, some of which may be responsible for the nontypeable phenotype.
Nonsusceptibility to tetracycline and erythromycin was higher in NTPn than encapsulated S. pneumoniae.
Conclusions: NTPn are currently a rare cause of invasive pneumococcal disease in South Africa and represent a
genetically diverse collection of isolates.
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Background
Streptococcus pneumoniae frequently colonizes the naso-
pharynx asymptomatically and is also a significant hu-
man pathogen causing diseases such as otitis media,
pneumonia and meningitis [1]. The capsule is a major
virulence factor of S. pneumoniae, protecting it from
host cell-mediated phagocytosis [2]. The capsule induces
protective antibodies which provide protection against
pneumococcal disease, and serves as the basis for
current pneumococcal vaccines [3]. Based on the struc-
ture and antigenicity of the capsule, more than 90 sero-
types have been identified [4, 5].
Nontypeable pneumococci (NTPn) are not assigned a
serotype when using the Quellung reaction [6]. The in-
ability to do so may be due to low-level capsule expression
or novel capsule types not detectable by the Quellung re-
action, or absence of capsule due to genetic modifications
in the capsular polysaccharide synthesis locus (cps)
[7–11]. NTPn are predominantly detected in carriage or
non-invasive disease episodes, and rarely cause invasive
pneumococcal disease (IPD) [12–14]. In vitro studies
have shown that NTPn display increased adherence to
epithelial cells and are more easily transformable
compared to encapsulated S. pneumoniae (Ec-Sp) isolates
[15, 16].
NTPn have been categorized into two groups based on
the contents of the cps locus [7]. Group I has at least
partial cps genes, whereas in Group II the cps genes are
completely deleted and may be replaced with other
genes. Group II is further subdivided into four null cap-
sule clades (NCC) [17]. NCC1 has the psk gene which
has been shown to play a role in adherence to epithelial
cells and colonisation [18]. NCC2 has aliC and aliD
genes either with (NCC2a) or without (NCC2b) a pu-
tative toxin-antitoxin system (encoded by ntaAB
genes). AliC and aliD genes facilitate upregulation of
competence for genetic transformation and mediate
colonization, respectively [19]. NCC3 has the aliD
gene, and NCC4 contains only transposable elements
in the cps locus.
There are limited studies describing invasive NTPn
[10, 12], possibly due to the rarity of these isolates in
IPD. The prevalence of NTPn as a cause of IPD has
been reported to range from 0.6 to 3 % [10, 12]. The ma-
jority (~90 %) of invasive NTPn described in the litera-
ture is Group I and is thought to be derived from Ec-Sp
[10, 12]. In contrast, almost all Group II isolates are re-
lated to established NTPn lineages [12]. Exploring the
potential changes in cps structure and understanding the
genomic diversity of NTPn is of importance, especially
because current pneumococcal conjugate vaccines (PCV)
are not effective against these isolates. We aimed to
describe disease and genotypically characterize NTPn
causing IPD in South Africa.
Results
Invasive pneumococcal disease surveillance in South Africa,
2003–2013
From 2003 through 2013, 46,485 cases of IPD were re-
ported, of which 32,824 (71 %) had viable isolates.
Thirty-nine (0.1 %) were nontypeable by the Quellung
reaction and were thus classified as NTPn. Case charac-
teristics are shown in Table 1. Forty-four percent (17/38)
of cases were in children <5 years. Two patients with
known vaccination status had received one dose of PCV13
and two doses of PCV7, respectively. Thirteen percent
(2/15) of patients with known immune status were immu-
nocomprised. Of ten patients with known HIV status,
50 % (5/10) were seropositive. Twenty-two percent (4/18)
of patients with known outcome data died.
Classification of NTPn and multi-locus sequence type
Fifty-six percent (22/39) of NTPn had at least partial cps
genes and were thus categorized as Group I (Table 2).
The remaining isolates (17/39, 44 %) had complete dele-
tion of cps genes (n = 17) and replacement by pspK (n = 1),
aliC, aliD and ntaAB (n = 12) or aliC and aliD genes only
(n = 2) and were thus categorized as Group II. Based on
the classification proposed by Park et al. [12, 17], these
isolates were defined as NCC1 (n = 1), NCC2a (n = 12),
NCC2b (n = 2) and NCC4 (n = 2).
A total of 28 STs were identified (Table 2). Among
Group I isolates, 18 STs were identified: 6 were novel
STs and 12 were STs usually associated with Ec-Sp.
Among Group II isolates, 10 STs were identified: 7 were
novel STs and 3 (NCC2a) were ST344 which is usually
associated with carriage NTPn, and ST105 and ST218
(NCC4) which are associated with Ec-Sp. Two CCs were
identified among Group I isolates; CC217 (n = 6) and
CC53 (n = 3) (Fig. 1). The remainder (n = 12) of Group I
isolates were not assigned to any CC, except for ST5604
which is a single-locus variant of a ST105 isolate from
Group II. CC344 (n = 6) was identified among Group II
isolates. The remainder (n = 10) of Group II isolates
were not assigned to any CC.
Predicted ancestral serotypes of Group I isolates
The most common predicted ancestral serotypes were
serotype 1 (n = 6), 8 (n = 3), 12F (n = 2), 6A (n = 2) and
14 (n = 2). Fifty-nine percent (13/22) of the predicted an-
cestral serotypes were PCV13 serotypes 1 (n = 6), 18C,
19A, 6A (n = 2), 14 (n = 2) and 23F (Table 2). Two of the
NTPn isolates (NT224 and NT225) were detected in
two patients that were co-infected with a serotype 1 and
serotype 18C isolate, respectively.
cps mutations in Group I isolates
Comparisons between Group I isolates and their ances-
tral serotype cps regions revealed a variety of mutations
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N = 39 N = 32785 N = 32824
n (%) n (%) n (%)
Year 2003 2 (5) 2885 (9) 2887 (9)
2004 4 (10) 3465 (11) 3469 (11)
2005 5 (13) 3643 (11) 3648 (11)
2006 5 (13) 3411 (10) 3416 (10)
2007 2 (5) 3318 (10) 3320 (10)
2008 6 (15) 3319 (10) 3325 (10)
2009 7 (18) 3377 (10) 3384 (10)
2010 3 (8) 2869 (9) 2872 (9)
2011 0 2409 (7) 2409 (7)
2012 3 (8) 2158 (7) 2161 (7)
2013 2 (5) 1931 (6) 1933 (6)
Gender Male 23 (59) 15842 (48) 15865 (48)
Female 16 (41) 16291 (50) 16307 (50)
Unknown 0 652 (2) 652 (2)
Age group (years) <5 17 (44) 9446 (29) 9463 (29)
5–14 3 (8) 2960 (9) 2963 (9)
15–24 2 (5) 1918 (6) 1920 (6)
25–44 10 (26) 11714 (36) 11724 (36)
45–64 4 (10) 4355 (13) 4359 (13)
>64 2 (5) 1137 (3) 1139 (3)
Unknown 1 (3) 1255 (4) 1256 (4)
Specimen type Cerebrospinal fluid 11 (28) 11486 (35) 11497 (35)
Blood 22 (56) 19284 (59) 19306 (59)
Othera 6 (16) 2015 (6) 2021 (6)
PCV vaccinationb Yesc 2 (100) 580 (77) 582 (77)
No 0 131 (17) 131 (17)
Unknown 0 46 (6) 46 (6)
PCV13 serotypesd PCV13 serotypes 13e (59) 23619 (72) 23632 (72)
Non PCV13 serotypes 9e (41) 9166 (28) 9175 (28)
HIV status Positive 5 (13) 7718 (23) 7723 (23)
Negative 5 (13) 2489 (8) 2494 (8)
Unknown 29 (74) 22578 (69) 22607 (69)
Immuno compromising conditionsf Yes 2 (5) 3114 (10) 3116 (10)
No 13 (33) 6974 (21) 6987 (21)
Unknown 24 (62) 22697 (69) 22721 (69)
Comorbid conditionsg Yes 2 (5) 1496 (5) 1498 (5)
No 13 (33) 8592 (26) 8605 (26)
Unknown 24 (62) 22697 (69) 22721 (69)
Outcome Died 4 (10) 4024 (12) 4028 (12)
Recovered 14 (36) 9887 (30) 9901 (30)
Unknown 21 (54) 18874 (58) 18895 (58)
aOther specimen types: pleural, joint and vitreous fluid
bOnly children born after February 2009 were included
cReceived at least 1 dose of the vaccine
dPCV13 serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 5, 7F, 3, 6A and 19A
eNontypeable predicted ancestral serotypes for Group I isolates
fImmunocompromising conditions were defined as medical record-documented pre-existing history of head injury, connective tissue disease, asplenia, pregnancy,
premature birth, malignancy, burns, gastric acid suppression, aplastic anemia, organ transplant, primary immunodeficiency conditions, chromosomal conditions,
protein energy malnutrition, alcohol dependency, current smoking, or immunosuppressive therapy
gComorbid conditions were defined as medical record-documented pre-existing history of pulmonary disease, renal disease, cerebrovascular accident, hepatic
disease, cardiac disease, or diabetes mellitus
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within the cps region of Group I isolates. These muta-
tions are summarized in Table 2, described in detail in
Additional file 1 and sketched in Additional file 2.
Briefly, predicted ancestral serotype 1 isolates had
identical partial deletions of cps genes (NT11, NT12,
NT17, NT18, NT45 and NT224). Isolate NT5 also had
partial deletions. The remaining isolates had almost all
cps genes present, as in their ancestral serotypes;
however, we identified a variety of mutations [single
nucleotide polymorphisms (SNPs), insertions and dele-
tions] in some of the cps genes. Most isolates had a
combination of mutations. The vast majority of SNPs
resulted in amino acid changes and a small number in
stop codons. Base deletions and insertions were not
common as SNPs.
Phylogenomic analysis
Ancestral serotype prediction was further confirmed by
phylogenomic clustering of Group I isolates with repre-
sentative genomes of their predicted ancestral serotypes
(Fig. 2). An exception was NT30 which was predicted to
be derived from serotype 16F but was more closely re-
lated to serotype 11A. For some isolates, there was more
divergence between the NTPn and their ancestral sero-
types as indicated by the long branches. Group II NCC1
(NT38), NCC4 (NT28 and NT33) and two carriage
NTPn (MNZ37 and MNZ11b) from other studies [20]
also clustered with invasive Ec-Sp and appear to be re-
lated to serotypes 3, 7F, 25A and 15A, respectively.
Group II NCC2 NTPn belonging to ST9811 (n = 5) and
ST10240 formed a distinct clade separate from other
Table 2 Classification, predicted ancestral serotypes and cps mutations of invasive nontypeable Streptococcus pneumoniae in South
Africa, 2003–2013 (N = 39)
Bold type represents serotypes included in PCV13
SLV single-locus variant, differs at one of the seven alleles. DLV Double-locus variant, differs at two of the seven alleles
None Novel ST and therefore no serotype/ST association exists
ND not done, isolates have no cps genes
N/A Not applicable, resembles nontypeable pneumococci from carriage (no cps genes, but instead have typical nontypeable genes)
NP not predicted. Isolates have no cps genes and/or are associated with more than 1 serotype
aAs per Streptococcus pneumoniae multilocus sequence typing database (http://pubmlst.org/spneumoniae/, accessed March 2015)
bOther serotype/s associated with that ST. See comments
cglf pseudo gene present within the cps locus
Mohale et al. BMC Genomics  (2016) 17:470 Page 4 of 11
Group II NCC2 isolates and seem to be more closely re-
lated to invasive Ec-Sp. The remaining Group II NCC2
NTPn (n = 8) formed a distinct clade with carriage
NTPn from other studies (n = 4) [20, 21]. Overall, 31/39
(79 %) of NTPn from this study ([22] Group I, Group II
NCC1 (n = 1), NCC4 (n = 2) and six NCC2 isolates be-
longing to ST9811 (n = 5) and ST10240) appear to have
been derived from Ec-Sp.
Antimicrobial resistance patterns
Nonsusceptibility among NTPn was highest for cotri-
moxazole (17/39, 44 %), penicillin (14/39, 36 %), tetra-
cycline (13/39, 33 %) and erythromycin (12/39, 31 %)
(Fig. 3). Prevalence of nonsusceptibility was higher
among NTPn than Ec-Sp for most antimicrobials; how-
ever this difference was only significant for tetracycline
[33 % (13/39) versus 18 %, (5902/32785), P = 0.02] and
erythromycin [31 % (12/39) versus 14 % (4589/32785),
P = 0.005]. In addition, 31 % (12/39) of NTPn were multi-
drug resistant [of which 21 % (8/39) included penicillin]
compared to 19 % (6230/32785) of Ec-Sp however this dif-
ference was not statistically significant (P = 0.09). With the
exception of cotrimoxazole and chloramphenicol, Group
II NTPn had a higher prevalence of nonsusceptibility than
Group I, although this difference was only statistically sig-
nificant for penicillin [59 % (10/17) versus 18 % (4/22),
P = 0.02] and erythromycin [53 % (9/17) versus 14 %
(3/22), P = 0.01]. Multidrug resistance was also higher
in Group II NTPn (47 %, 8/17) compared to Group I
(18 %, 4/22), although not statistically significant (P =
0.08).
Discussion
We characterized NTPn causing IPD in South Africa, a
middle-income, high HIV prevalence country with PCV
introduction in 2009. NTPn represented 0.1 % of IPD
cases, much lower than other studies which have re-
ported a prevalence of between 0.6 and 3 % [10, 12].
Our study showed that among patients with NTPn in-
fection and for whom data were available, 44 % were
children less than 5 years, proportionately more than
Ec-Sp (29 %), 50 % were HIV positive versus 76 % for
Ec-Sp and the case-fatality ratio (22 %) was similar to
cases with Ec-Sp (29 %). Fifty-six percent of our NTPn
were Group I, for which the most common predicted
ancestral serotypes were 1 (27 %) and 8 (14 %). Fifty-
nine percent of the predicted ancestral serotypes were
PCV13 serotypes. The cps loci of the Group I isolates
harbored a variety of mutations. Nonsusceptibility to
tetracycline and erythromycin was significantly higher in
NTPn than encapsulated S. pneumoniae. Nonsuscept-
ibility to penicillin and erythromycin was also signifi-
cantly higher in Group II NTPn than Group I.
The mechanisms by which NTPn are able to cause
IPD without the capsule are not clear. Immune suppres-
sion of the host and/or other lesser known or novel viru-
lence factors might possibly explain the success of
NTPn in causing IPD. However, in this study the
Fig. 1 eBURST population snapshot showing relationships among sequence types (ST) identified in Group I (n = 22) and Group II (n = 17) invasive
nontypeable Streptococcus pneumoniae in South Africa (2003–2013). The size of each circle corresponds with the number of isolates. Clusters of linked
isolates correspond to clonal complexes (isolates sharing six of seven alleles) and blue indicates the founding genotype. New STs are underlined
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Fig. 2 Maximum likelihood phylogenetic tree based on core genome SNPs of invasive nontypeable Streptococcus pneumoniae (n = 39), shown in
red and yellow from South Africa (2003–2013). Encapsulated S. pneumoniae (representative of predicted ancestral serotypes) from South Africa
(n= 42, shown in blue) and publically available nonencapsulated S. pneumoniae genomes ([20, 21] (n= 6, indicated green) were included for comparison
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majority of patients with NTPn infection (87 %, 13/15)
were not immunocompromised and this was similar to
patients with Ec-Sp strains (69 %). NTPn appear to be
equally as virulent as Ec-Sp as the patients with NTPn
infection did not seem to be more susceptible to
infection.
We observed a higher prevalence (44 %) of Group II
isolates amongst our NTPn that has not been described
in other studies, where 4 to 10 % of NTPn were Group
II isolates [10, 12]. The majority of Group II isolates
(82 %) were NCC2 and no isolates belonging to NCC3
were identified, a finding similar to invasive NTPn col-
lected through the Active Bacterial Core surveillance
program in the United States during 2006–2009 [12]. In
addition, two isolates were classified as NCC4, a newly
defined clade in Group II, characterized by deletion of
all cps genes [12]. Similar to what has been shown in the
US Active Bacterial Core surveillance, NCC4 isolates in
this study also appeared to be derived from Ec-Sp [12].
We were able to predict ancestral serotypes for all
Group I isolates because they had partial cps genes, sug-
gesting that these isolates were derived from Ec-Sp
which, at some point, lost their capsule through muta-
tions in the cps locus. Indeed we found a diverse range
of mutations in the cps locus of Group I isolates, some
of which may be responsible for the nontypeable pheno-
type. For predicted ancestral serotype 1 isolates, all cps
mutations were identical. The deleted region is flanked
by identical IS1167 repeats and this, together with the fact
that the predicted ancestral serotype 1 isolates were geno-
typically related, indicates that the cps mutations probably
occurred as a result of a single deletion event in a particu-
lar strain rather than multiple independent deletions in
different strains. The same mutations have been described
for serotype 1-derived NTPn in other studies [9, 10].
Serotype predictions were confirmed by the phyloge-
nomic analyses as these isolates clustered with encapsu-
lated strains expressing the same serotype as the
predicted ancestral serotypes. One isolate (NT30), how-
ever, was more closely related to serotype 11A than its
predicted serotype 16F. This isolate has a novel ST,
which shares three of seven alleles with the 11A isolate,
suggesting that NT30 may have been derived from a
common ancestor with serotype 11A at some point in
time. For some isolates, there was more divergence be-
tween the NTPn and their ancestral serotypes. This
could be that certain serotypes are inherently diverse
while others are more stable.
Predicted ancestral serotypes 1 (27 %) and 8 (14 %)
were most prevalent among our NTPn isolates. Analysis
of invasive NTPn isolates from Native American com-
munities collected from 1994–2007 showed that pre-
dicted ancestral serotype 1 (19 %) and 7 F (15 %) were
most prevalent [10]. In addition, serotype 8 (25 %) was
most prevalent among invasive NTPn from the US Ac-
tive Bacterial Core surveillance [12]. These data suggest
Fig. 3 Antimicrobial nonsusceptibility of Streptococcus pneumoniae isolates causing invasive disease in South Africa, 2003–2013
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that serotypes 1 and 8 may be more prone to mutations
in their cps region than other serotypes.
Two of the NTPn isolates (NT224 and NT225) were
detected in mixed infections in two patients with encap-
sulated serotype 1 and 18C isolates, respectively. For the
serotype 1 and NT224 mixed infection, S. pneumoniae
was identified from the same culture, with the NT iso-
late representing approximately 98 % of the culture
(using the Quellung reaction). After several attempts to
separate the two variants, only the NTPn isolate could
be obtained, however, real-time PCR confirmed the pres-
ence of the serotype 1 in the mixed culture. NT224 was
confirmed to be ST217 which is associated with serotype 1.
For the serotype 18C and NT225 mixed infection, both
isolates were available and NT225 had the same cps region,
with the exception of a single SNP, compared to its encap-
sulated counterpart (serotype 18C), the same ST and their
core genomes were identical (unpublished observations).
Pneumococcal serotypes targeted by PCV have the po-
tential to switch from vaccine serotype to non-vaccine
serotype or to nontypeable, thereby providing a mechan-
ism whereby they may be able to evade vaccine pressure.
However, no evidence of adaptation to PCV occurred
among invasive NTPn from Native American communi-
ties, where 45 % of NTPn isolates had ancestral PCV7
serotypes pre-vaccine and none of their NTPn isolates
were ancestral PCV7 serotypes post-vaccine [10]. Al-
though 59 % of the predicted ancestral serotypes of
NTPn in our study were PCV13 serotypes, there is no
evidence to suggest that serotype switching occurred as
a result of PCV pressure as the majority of NTPn were
already present prior to PCV introduction.
Antimicrobial nonsusceptibility data for invasive
NTPn are limited. In our study, there was a significantly
higher prevalence of nonsusceptibility among NTPn
than Ec-Sp for erythromycin and tetracycline. These
higher nonsusceptibility rates coupled with higher trans-
formation rates of NTPn [16] enable these strains to
serve as a reservoir of antibiotic resistance genes. A
serotype 19F clone from Switzerland became increas-
ingly resistant to penicillin by acquisition of a pbp2x
gene from NTPn [23]. Recently, a comparative genome
analysis of over 3000 carriage pneumococci from a refu-
gee camp in Thailand showed that the highest rates of
receipt and donation of recombinant of DNA occurred
in NTPn and that the most commonly exchanged genes
were those associated with antibiotic resistance and
immune interactions [24].
It is possible that our NTPn isolates may have lost the
ability to express capsule during sub-culturing in the
laboratory, but we believe this was not the case as we
would expect NTPn to be detected more frequently. We
did not perform in vitro experiments to confirm whether
the mutations identified in the cps locus of our isolates
were responsible for the lack of capsule expression.
However, in some of these isolates, there were complete
deletions of cps genes making expression of a capsule
impossible. For Ec-Sp isolates different methods [agar
dilution or Etest (2003–2008) or broth microdilution
(2009–2013)] were used for MIC testing compared to
NTPn (broth microdilution). This may have overestimated
the prevalence of β-lactam resistance in NTPn for the
2003–2008 period as broth microdilution detects more re-
sistance than agar dilution as was previously shown [25].
Conclusion
NTPn are currently a rare cause of IPD in South Africa
and are genetically diverse but have a higher prevalence
of antimicrobial resistance than Ec-Sp. The majority of
NTPn were derived from Ec-Sp, of which a significant
proportion was PCV13 serotypes. Further studies which
explore capsule-independent virulence mechanisms of
NTPn should be considered.
Methods
Bacterial isolates
Isolates were obtained through the GERMS-SA (Group
for Enteric, Respiratory and Meningeal Disease Surveil-
lance in South Africa) network, which conducts active,
national, laboratory-based surveillance for IPD. Surveil-
lance began in 1999 and was enhanced in 2003 [26, 27].
Over 200 diagnostic laboratories across South Africa
routinely submit clinical isolates and basic patient demo-
graphic data to the network. A case of IPD was defined
as the detection of S. pneumoniae from a normally ster-
ile site (e.g., cerebrospinal fluid, blood) from January
2003 through December 2013. Isolates were cultured on
5 % horse blood agar (Diagnostic Media Products, Jo-
hannesburg, South Africa) and incubated at 37 °C in 5 %
CO2 for 18–24 h. Optochin sensitivity and bile solubility
assays were performed to confirm S. pneumoniae identi-
fication. In addition, for NTPn isolates, real-time PCR
detecting lytA was performed [28]. A mixed infection
was defined as simultaneous isolation of at least two sero-
types (including nontypeable isolates) either from the
same normally-sterile site specimen or from two or more
normally-sterile site specimens obtained from the same
patient within 21 days of each other. Such cases were de-
tected during routine serotyping by Quellung if an isolate
reacted partially with a specific antiserum pool.
Serotyping and antimicrobial susceptibility testing
Serotyping was performed by the Quellung reaction
using serotype-specific antisera (Statens Serum Institut,
Copenhagen, Denmark). Minimum inhibitory concentra-
tions (MIC) for NTPn isolates were determined by broth
microdilution using commercially customized TREK
panels (Trek Diagnostics Inc., Ohio, United States).
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MICs for Ec-Sp isolates were determined as previously
described [25, 27]. MIC breakpoints were interpreted
using Clinical and Laboratory Standards Institute guide-
lines [29]. For penicillin, isolates with MICs of ≥0.12 mg/L
were defined as nonsusceptible. Isolates that were inter-
mediately resistant or resistant to any of the antibiotics
were regarded as nonsusceptible. Multidrug resistance
was defined as nonsusceptibility to three or more classes
of antibiotics.
DNA preparations, genome sequencing and assembly
Brain heart infusion broth (Diagnostic Media Products)
was inoculated with overnight cultures and incubated
overnight at 37 °C in 5 % CO2. A pre-lysis step was per-
formed by suspending bacterial pellets in 200 μl of
10 mg/ml lysozyme (Sigma-Aldrich, St. Louis, MO, USA)
and incubating at 37 °C for 1 h. Genomic DNA was ex-
tracted using the QIAamp® DNA Mini kit (QIAGEN, Hil-
den, Germany). Paired-end libraries (2 x 300 bp) were
prepared using the Nextera XT DNA sample preparation
kit (Illumina, San Diego, CA, USA) and sequencing was
performed on an Illumina MiSeq. The resulting paired-
end reads were quality trimmed and mapped to the refer-
ence genome of S. pneumoniae ATCC 700669 [GenBank
accession no. FM211187, serotype 23 F, sequence type
(ST) 81] using CLC Genomics Workbench v8 (CLC bio,
Aarhus, Denmark), giving on average 121x depth of cover-
age and 88 % coverage of the reference genome. De novo
assembly was performed for all isolates using CLC Gen-
omics Workbench and ordered relative to S. pneumoniae
ATCC 700669 using Mauve [30]. The ordered contigs
were concatenated and annotated using Prokka v1.11 [31].
cps regions and multi-locus sequence typing (MLST)
The cps locus and seven MLST alleles were derived from
whole genome data. The cps loci were used to categorize
NTPn into different groups/clades [12, 17]. MLST allele
numbers and sequence type (ST) were assigned using the
Bio-MLST-Check module (http://search.cpan.org/~ajpage/
Bio-MLST-Check 1.133090/lib/Bio/MLST/Check.pm). The
eBURST v3 algorithm (http://eburst.mlst.net) was used to
determine genetic relationships and grouped isolates into
clonal complexes (CC) [32]. A CC was defined as a group
of isolates sharing six of seven alleles with any other isolate
in the group.
In silico prediction of ancestral serotypes for Group I NTPn
To predict ancestral serotypes of Group I isolates (serotypes
from which NTPn may have originated), two methods were
used, namely, serotype-ST associations using the MLST
database (http://pubmlst.org/spneumoniae), accessed March
2015, and blasting of the cps locus against reference cps
loci for the 94 known serotypes (GenBank accession
no’s. CR93162 – CR931722, EF538714, HM171374,
GU074953 and JQ653094). The serotype that gave the
highest BLAST bit score was assigned as the likely an-
cestral serotype.
cps mutations in Group I NTPn
To determine the genetic variations within the cps locus
of Group I isolates that may be responsible for their
phenotypic nontypeability, we used the alignment mod-
ule in CLC to align the cps locus of each isolate together
with a number of its predicted ancestral serotype cps loci
shown in Additional file 3.
Phylogenomic tree construction
To confirm predicted ancestral serotypes for Group I
isolates, a maximum likelihood phylogenetic tree was
constructed based on core genome SNPs of NTPn from
this study (n = 39), together with invasive Ec-Sp with dif-
ferent serotypes from South Africa (n = 42) Additional
file 4 matching the predicted ancestral serotypes for the
NTPn isolates, and carriage NTPn from other countries
(n = 6) [20, 21]. The core genome alignment module in
the rapid large-scale prokaryote pan genome analysis
pipeline was used to extract predicted coding regions
from annotated assemblies and convert them to protein
sequences [33]. All protein sequences were compared
with each other using BLASTP. Proteins that had align-
ment similarity of ≥70 % and were present in at least 90 %
of the isolates were defined as the core genome. RAxML
was used to create a phylogenetic tree from the resulting
core genome alignment and this was visualized in Figtree
v1.4.2 [34].
Statistical analysis
Differences between NTPn versus Ec-Sp antimicrobial
nonsusceptibility and between Group I and Group II
NTPn were analyzed using the chi-square test and Fisher’s
exact test, respectively, with statistical significance assessed
at P < 0.05. Statistical analyses were performed with
GraphPad InStat 3.
Additional files
Additional file 1: Description of the cps mutations of nontypeable
Streptococcus pneumoniae (n= 39) from South Africa, 2003–2013. (XLS 44 kb)
Additional file 2: Diagrammatic representation of capsular locus of
nontypeable Streptococcus pneumoniae (n = 39) from South Africa,
2003–2013. (DOCX 1547 kb)
Additional file 3: Accession numbers for encapsulated S. pneumoniae
used for cps locus alignment (XLS 54 kb)
Additional file 4: Accession numbers for encapsulated S. pneumoniae
isolates from South Africa and carriage nontypeable isolates from other
studies used to construct the phylogenetic tree. (XLS 34 kb)
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